Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
Browsing: Drug development
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
Frontage Holdings Corporation announces successful initial public offering on the Hong Kong stock exchange
Frontage Holdings Corporation has recently announced that they have begun trading on the main board of the stock exchange of Hong Kong.
This commentary from Bioanalysis focuses on the status of drug detection with metal nanoparticles as ultrasmall labels in colorimetric-based methods.
Discover more about how Charles River (MA, USA) employs flow cytometry to support mouse model development in this interview with Christoph Eberle and Stephen Festin.
Global leaders in life sciences and nonclinical drug development, Envigo (Huntingdon, UK) and LabCorp (NC, USA), have signed an innovative agreement in a bid to expand nonclinical drug development capabilities and create an independent research models provider.
With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
Find out more about the latest news and developments in labs-on-chips in the investigation of gut inflammation and cellular responses in drug discovery in this round-up.
Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum
In this manuscript, the European Bioanalysis Forum presents additional practice guidance on the use of flow cytometry in the support of drug development programs and addresses areas that are not covered in the previous publications.
In this editorial Yu Shrike Zhang (Harvard Medical School; MA, USA), a previous finalist of the Bioanalysis Rising Star Award, discusses his research and hopes for the future. He details the emergence of organ-on-a-chip systems and how these platforms reproduce tissue functions outside the human body.